Literature DB >> 3495440

The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.

J Karbwang, D Bunnag, A M Breckenridge, D J Back.   

Abstract

The kinetics of mefloquine were studied in 12 healthy Thai male and 12 healthy Thai female volunteers. Mefloquine (MQ) was administered either alone (750 mg orally) or in combination (MSP) with sulphadoxine (1.5 g) and pyrimethamine (75 mg) to each of 6 male and 6 female subjects. Plasma concentrations of MQ were measured by HPLC at intervals for 42 days. There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1. Compared to previously published data on MQ concentrations in Caucasian male subjects, the present study indicates that higher concentrations are achieved in Thai subjects. The only significant difference in kinetic parameters between male and female subjects receiving MQ alone was in the mean residence time (MRT) which was greater in females. However, an analysis of pharmacokinetic parameters following administration of the combination preparation showed that the time to peak (tmax) was significantly reduced in females receiving MSP compared to the corresponding females given MQ alone and males given MSP. When data obtained from all subjects (male and female) receiving either MQ alone or MSP were combined, both MRT and half-life were significantly greater in subjects given MSP. There is therefore some evidence that therapeutic concentrations of MQ are maintained for a longer period of time following MSP administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495440     DOI: 10.1007/BF00542191

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Antimalarials. 7. Bis(trifluoromethyl)- -(2-piperidyl)-4-quinolinemethanols.

Authors:  C J Ohnmacht; A R Patel; R E Lutz
Journal:  J Med Chem       Date:  1971-10       Impact factor: 7.446

3.  Mefloquine (WR 142,490) in the treatment of human malaria.

Authors:  C M Trenholme; R L Williams; R E Desjardins; H Frischer; P E Carson; K H Rieckmann; C J Canfield
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

4.  In vivo and in vitro sensitivity of Falciparum malaria to quinine in Thai children.

Authors:  T Chongsuphajaisiddhi; A Sabcharoen; P Attanath
Journal:  Ann Trop Paediatr       Date:  1981-03

5.  Multiple-dose kinetic study of mefloquine in healthy male volunteers.

Authors:  I Mimica; W Fry; G Eckert; D E Schwartz
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

Review 6.  Recent advances in malaria with special reference to Southeast Asia.

Authors:  T Harinasuta; K E Dixon; D A Warrell; E B Doberstyn
Journal:  Southeast Asian J Trop Med Public Health       Date:  1982-03       Impact factor: 0.267

7.  Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria.

Authors:  A P Hall; E B Doberstyn; C Karnchanachetanee; S Samransamruajkit; B Laixuthai; E J Pearlman; R M Lampe; C F Miller; P Phintuyothin
Journal:  Br Med J       Date:  1977-06-25

8.  Suppressive activity of mefloquine in sporozoite-induced human malaria.

Authors:  D F Clyde; V C McCarthy; R M Miller; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

9.  Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug-resistant malaria.

Authors:  K H Rieckmann; G M Trenholme; R L Williams; P E Carson; H Frischer; R E Desjardins
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

10.  The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'.

Authors:  W Peters; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1984-10
View more
  20 in total

1.  Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.

Authors:  J A Kolawole; A Mustapha; I Abudu-Aguye; N Ochekpe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Effect of ampicillin on mefloquine pharmacokinetics in Thai males.

Authors:  J Karbwang; K Na Bangchang; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Antimalarial agents: specific treatment regimens.

Authors:  D J Krogstad; B L Herwaldt; P H Schlesinger
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.

Authors:  F Nosten; J Karbwang; N J White; K Na Bangchang; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

7.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 9.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

10.  Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.